Addressing Unmet Medical Needs

Biologics and Small Molecule Drugs

Edesa Biotech, Inc.

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company exploring new ways to treat inflammatory and immune-related diseases, including alternatives to topical steroids.

For decades there have been no new effective treatment options for the disorders Edesa is addressing.

Image of Topical Cream Being Applied to Rash on Hand

Inhibiting the Inflammation Cascade

We believe that our technology, called sPLA2 inhibitors, will have a superior therapeutic effect because the inflammatory process will be inhibited at its inception rather than after inflammation has occurred.

Allergic Contact Dermatitis

Our lead product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. In two clinical studies, this topical therapy has demonstrated significant improvement of multiple symptoms in contact dermatitis patients. Edesa also intends to expand the utility of our sPLA2 inhibitor technology across multiple indications.

sPLA2 Inhibitors

Countering Hyper-Immune Responses

Our novel monoclonal antibodies suppress certain immune signaling proteins, known as TLR4 and CXCL10. These molecules are associated with a broad range of diseases, including infectious diseases like COVID-19.

Addressing the Global Health Crisis

We have prioritized the study of our novel monoclonal antibodies in moderate to severe COVID-19 patients, where inflammation and injury to the lungs is often the result of an overactive immune response, sometimes described as a “cytokine storm.” Our antibody therapies are intended to inhibit this cytokine storm and the inflammation, fluid accumulation and lung injury it causes.

TLR4 and CXCL10 Inhibitors